Methoxphenidine

<p>Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a <a href="/facts/Dissociative_drug/5aaD39vM">dissociative</a> of the diarylethylamine class that has been sold online as a <a href="/facts/Designer_drug/QWFd3KV4">designer drug</a>. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound <a href="/facts/Diphenidine/nTCuGCrQ">diphenidine</a> became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric <a href="/facts/Anisole/ezvjrK1s">anisyl</a>-substituents methoxphenidine has affinity for the <a href="/facts/NMDA_receptor/BqMhXEbU">NMDA receptor</a> that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine, a <a href="/facts/Structure%E2%80%93activity_relationship/S2RxpCUK">structure–activity relationship</a> shared by the <a href="/facts/Arylcyclohexylamine/x4MVvTyJ">arylcyclohexylamines</a>.
</p>

Methoxphenidine open-in-new

Methoxphenidine